Improving treatment outcome for children with HIV
Over 2 million children are infected with HIV, and around 700 children die of HIV/AIDS-related causes every day. Almost all children with HIV infection have been infected through perinatal transmission, and without antiretroviral treat ment over half will die before the age of 2 years.
1 Antiretrovirals have had a dramatic eff ect on the course of HIV/AIDS in children. Trials show excellent long-term outcomes with protease inhibitors and non-nucleoside reverse-transcriptase inhibitors, 2 and current guidelines recommend starting antiretroviral therapy in children as soon as possible after diagnosis of HIV infection. 3 Poor availability of effi cient antiretroviral regimens, unclear strategies for optimum drug sequencing, and maintenance of high adherence from infancy and throughout adolescence to adulthood are important challenges to long-term treatment success. 4 In The Lancet, the PLATO II investigators 5 report a cohort collaboration in Europe which assessed the risk of triple-class virological failure in children. Just over 1000 children were followed up for a median of 4·2 years. By the end of follow-up, 335 (33%) had started a drug from a third class, of whom 105 were on a failing regimen. The estimated cumulative proportion of children with triple-class virological failure was 12% at 5 years; when the analysis was restricted to children exposed to boosted protease inhibitors, the cumulative proportion was about twice that seen in adults in the same cohort collaboration (8·2% vs 4·2%). Older age when starting antiretroviral therapy (10-15 years) was associated with an increased risk of triple-class virological failure, but among all those who had such virological failure, about a quarter never achieved virological suppression; the average age of this group was less than 2 years.
Evidence from treatment programmes supports the feasibility and benefi ts of antiretroviral therapy, even in highly under-resourced settings, 6 and the results from PLATO II need to be considered in context: more than a quarter of patients in the cohort had started treatment before 2000 when less potent treatments were used and treatment guidelines were poorly standardised.
Nevertheless, these data raise several concerns. Although the overall rate of triple-class virological failure was low, treatment durability is more crucial in children than in adults. Achieving sustained virological suppression is the goal irrespective of the patient's age, and the fact that very young children might never achieve virological suppression is cause for concern. For young children, whose adherence depends on caregivers, treatment options are extremely limited and poorly adapted. Of the 22 antiretroviral drugs currently approved by the US Food and Drug Administration, fi ve are not approved for use in children and six are not available in paediatric formulations. 7 Additionally, treatment has to be constantly adjusted for bodyweight, and most paediatric antiretrovirals are formulated as syrups (often in large volumes) which are diffi cult to administer and store, while boosted protease inhibitors are extremely unpalatable. Such complications contribute to the explanation of why, in PLATO II and other studies, 8, 9 children are more prone to virological failure than are adults.
These issues are all the more important in resourcelimited settings, where over 90% of children living with HIV/AIDS reside. WHO and treatment providers, such as Médecins Sans Frontières, are pressing for more widespread use of solid formulations, including fi xeddose combinations. Currently only four quality-assured triple-drug fi xed-dose combinations are available in solid and dispersible forms from manu facturers of generic drugs, and less desirable dose formulations continue to dominate this small and fragmented market. 10 The PENPACT-1 (PENTA 9/PACTG390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in
